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ABSTRACT 43 
Background and aims: Obesity is frequently associated with non-alcoholic fatty liver disease 44 
(NAFLD), insulin resistance (IR), inflammation and metabolic syndrome (MetS) all of which 45 
increase risk of type 2 diabetes (T2DM). However, the role of these risk factors in mediating 46 
the effect of obesity remains unclear. We investigated the association between obesity and 47 
T2DM in the absence and presence of NAFLD, IR, inflammation and MetS components. 48 
Methods: 29,836 obese people without diabetes were studied in a Korean health screening 49 
program. Obesity was defined by the appropriate ethnic-specific body mass index (BMI) 50 
threshold ≥25kg/m2. Hazard ratios (HRs and 95% confidence Intervals, CIs) for incident T2DM 51 
were estimated for the group with none of hypertension, dyslipidemia, impaired fasting glucose, 52 
fatty liver, IR, or inflammation (n = 1,717), compared to the reference group, with one or more 53 
of these factors (n = 19,757). 54 
Results: Mean (SD) age at baseline was 37 (7) years and 1,200 incident cases of diabetes 55 
occurred. Crude T2D incidence was 12.6 /10,000 person-years in the group without metabolic 56 
abnormality and was 143/10,000 person-years in the reference group. HR (95% CIs) for 57 
incident diabetes was 0.13 (0.06, 0.33) in the group without metabolic abnormality. 58 
Conclusions: Obese subjects without components of the metabolic syndrome, IR, fatty liver 59 
and inflammation have an approximately 11 fold lower risk of incident type 2 diabetes than 60 
obese subjects who have these risk factors. These simple factors could be used to target limited 61 
resources at high risk obese subjects in the prevention of diabetes. 62 
 63 
Keywords: Obesity; Non alcoholic fatty liver disease; Type 2 diabetes; Insulin resistance; 64 
Inflammation; Metabolic syndrome  65 
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1. Introduction 66 
 67 
The prevalence of type 2 diabetes (T2DM) continues to increase across the world [1-3] 68 
and obesity is an important risk factor for T2DM. Non alcoholic fatty liver disease (NAFLD) 69 
and metabolic syndrome (MetS) are very common in obese individuals and also in subjects with 70 
T2DM) [4] and we have previously shown that approximately 90% of people who develop 71 
T2DM over ~5 years of follow up have one or more of obesity, insulin resistance and NAFLD 72 
[5]. Current population-based estimates of prevalence of NAFLD are approximately 30-40% in 73 
men and 15-20% in women [6], and in T2DM prevalence is as high as 70% [7]. The presence 74 
of NAFLD is associated with increased risk of T2DM in the majority of studies [5,8-17]. 75 
However, in these studies relative risk of T2DM varied markedly from a relatively small 64% 76 
increase [15], to a large 5.5 fold increase in risk [9]. This wide inter-study variation in risk of 77 
incident T2DM, suggests that variation in other risk factors associated with NAFLD, such as 78 
obesity, MetS, insulin resistance and inflammation, may be accounting for the marked 79 
differences in risk of T2DM between these studies. Consequently, it is important to know how 80 
obesity, with and without commonly associated risk factors such as NAFLD, inflammation, 81 
MetS and insulin resistance, influences risk of T2DM. 82 
Metabolically healthy obesity (MHO) is a term that has been used to define a group of 83 
obese individuals who do not also have metabolic abnormalities although some studies have 84 
still shown that subjects with MHO remain at higher risk of T2DM and cardiovascular disease 85 
(CVD) than non-obese individuals [18-20]. Indeed, the variable risk of diabetes in MHO 86 
subjects, may be explained by the different definitions that have been used to define MHO. 87 
Previously, exclusion of MetS components, but not NAFLD, has been used to define MHO [21], 88 
and therefore it is not clear whether assessment of NAFLD status could contribute to a clinically 89 
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useful, pragmatic definition of MHO, that could be used to identify obese subjects who are at 90 
low risk of developing diabetes. 91 
In a large, well phenotyped obese cohort, our aim was to investigate incidence and risk of 92 
T2DM in obese subjects with and without, fatty liver, inflammation, MetS components and 93 
insulin resistance. 94 
 95 
2. Materials and Methods 96 
 97 
The study population consisted of individuals who participated in a comprehensive health 98 
screening program, at least twice, at Kangbuk Samsung Hospital, Seoul and Suwon, Korea from 99 
2007 to 2014 (n = 219,417). Among these subjects, we excluded subjects with missing body 100 
mass index (BMI) data n = 7, non obese subjects, n = 157,478 (normal weight n = 95,408, 101 
underweight n = 10,717, overweight n = 51,282). We also excluded subjects aged < 20 years 102 
(n = 54), and subjects with heart disease, or stroke, subjects taking medication for stroke or 103 
hyperlipidemia (n = 17,272), subjects with diabetes (n = 7,505), hypertension (n = 27,454), 104 
history of cancer (n = 3,599) or with relevant missing data (n = 83) (N.B some subjects were 105 
excluded for having more than one exclusion criterion). 106 
Thus, we identified 29,836 obese subjects who were included in this analysis and the 107 
mean±SD [and median (IQR)] follow up period was 3.9±2.0 years, [3.8 (2.0-5.8)] years. The 108 
study was approved by the Institutional Review Board of Kangbuk Samsung Hospital and any 109 
requirement for informed consent was waived by the Board because de-identified information 110 
was retrieved retrospectively. 111 
 112 
2.1. Measurements 113 
As part of the health screening program, individuals completed self-administered 114 
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questionnaires, related to their medical and social history and medication usage. Individuals 115 
were asked about duration of education (years), regular exercise, smoking history (never, 116 
former, or current) and alcohol consumption (grams, g/week). Trained staff also collected 117 
anthropometric measurements and vital statistics. Body weight was measured in light clothing 118 
with no shoes to the nearest 0.1 kilogram using a digital scale. Height was measured to the 119 
nearest 0.1 centimeter. BMI was calculated as weight in kilograms divided by height in meters 120 
squared. 121 
Blood samples were collected after at least 10-hours of fasting and samples were analyzed 122 
in the core clinical laboratory at the Kangbuk Samsung Hospital. The core clinical laboratory 123 
has been accredited and participates annually in inspections and surveys by the Korean 124 
Association of Quality Assurance for Clinical Laboratories. Serum levels of glucose, total 125 
cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density 126 
lipoprotein cholesterol (HDL-C) were measured using Bayer Reagent Packs (Bayer 127 
Diagnostics, Leverkusen, Germany) on an automated chemistry analyzer (Advia 1650 128 
Autoanalyzer; Bayer Diagnostics, Leverkusen, Germany). Insulin was measured with an 129 
immunoradiometric assay (Biosource, Nivelle, Belgium) and insulin resistance was defined by 130 
a HOMA-IR≥2.5. MetS was defined according to the Joint Societies 2009 criteria for MetS 131 
[22]. We defined obesity in this Asian population by a BMI ≥ 25(kg/m2). High sensitivity-C 132 
reactive protein (hsCRP) was analysed by particle-enhanced immunonephelometry with the 133 
BNIITM System (Dade Behring, Marburg, Germany) with a lower detection limit of 0.1 mg/L. 134 
A measurement of ≥1 mg/L was used to define subjects with inflammation. Gamma glutamyl 135 
transferase (GGT), aspartate amino transferase (AST), alanine amino transferase (ALT), 136 
concentrations were measured using Bayer Reagent Packs on an automated chemistry analyzer 137 
(Advia 1650 Autoanalyzer; Bayer Diagnostics, Leverkusen, Germany). Intra- and interassay 138 
coefficients of variation for all biochemical measurements were < 5%. 139 
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Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure 140 
≥90 mmHg, self-report history of hypertension, or current use of antihypertensive medication. 141 
Weekly frequency of exercise was assessed using the validated Korean version of the 142 
International Physical Activity Questionnaire Short Form (IPAQ-SF) [23]. Abdominal 143 
ultrasonography (Logic Q700 MR; GE, Milwaukee, WI, USA) was undertaken by clinical 144 
radiologists using a 3.5MHz probe for all subjects at baseline and after five years. The following 145 
images were undertaken; i) sagittal view of the right lobe of the liver and right kidney, ii) 146 
transverse view of the left lateral segment of the liver and spleen and iii) transverse view of the 147 
liver for altered echo texture. Fatty infiltration of the liver (fatty liver) was identified if there 148 
was an increase in echogenicity of the liver compared with the echogenicity of the renal cortex 149 
where the diaphragm and intrahepatic vessels appeared normal [24]. Diabetes was defined as a 150 
self-reported history of diabetes, the use of glucose-lowering medications and/or HbA1c ≥6.5% 151 
or fasting glucose ≥ 126mg/d at baseline (to exclude people with prevalent diabetes), and at 152 
follow-up (to identify incident diabetes). 153 
 154 
2.2. Statistical analyses 155 
The statistical analysis was performed using STATA version 15.0 (StataCorp LP, College 156 
Station, TX, USA). Reported p values were two-tailed, and < 0.05 were considered statistically 157 
significant. The distribution of continuous variables was evaluated and transformations were 158 
conducted for nonparametric variables. Cox proportional hazards models were used to estimate 159 
Hazard Ratios (HRs and 95% confidence intervals) (and fully adjusted HRs, aHRs) for the 160 
association between sub-groups and incident diabetes at follow up. Three mutually exclusive 161 
obesity groups were generated: 162 
Group A (reference group) (n = 19,757 (66.22%) = obese subjects with ≥1 component 163 
of MetS (i.e. dysglycaemia, low levels of HDL-C, or high levels of serum triglyceride 164 
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concentrations, or increased blood pressure [22]); or fatty liver (defined by presence of fatty 165 
liver on ultrasound), or IR (defined by HOMA-IR≥2.5), or inflammation (defined by 166 
hsCRP≥1mg/L). 167 
Group B (n = 8,362 (28.03%) = obese subjects without features of the MetS [22], but with 168 
≥1 of fatty liver, IR, or inflammation (defined as above). 169 
Group C (n = 1,717 (5.75%) = obese subjects without features of the MetS [22], fatty 170 
liver, IR or inflammation (defined as above). 171 
The proportional hazards model assumption was tested with a graphical analysis of the 172 
hazard of incident diabetes over time (see Supplementary Fig. 1). Models were adjusted for age, 173 
sex, center (Seoul or Suwon), year of screening exam, smoking status, alcohol intake, exercise, 174 
family history of diabetes and education level. 175 
 176 
3. Results 177 
 178 
The mean age ±SD (range) of the cohort was 37 ± 6 (range: 20-77) years. Table 1 describes 179 
the baseline characteristics of subjects who developed incident diabetes compared with 180 
characteristics of subjects remaining free from diabetes at follow up (mean±SD) 4±2 (range: 181 
0.5-8) years of follow up. With 114,119 person-years of follow up, and 1200 incident cases of 182 
T2DM, the incidence rate was 1.1% (95% CIs 1.0, 1.1) per annum. Subjects who developed 183 
incident diabetes were older, had a higher prevalence of fatty liver and had a higher BMI, hsCRP 184 
and HOMA-IR, than subjects who did not develop diabetes during follow-up. Table 2 (men) 185 
and Table 3 (women) show the baseline characteristics of the cohort in the three sub-groups of 186 
obesity according to the presence or absence of metabolic abnormalities as described in the 187 
Methods. 188 
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Since fatty liver often co-exists with T2DM [4], we investigated the association between 189 
fatty liver and incident T2DM. Adjusting for age, sex, center, year of screening exam, smoking 190 
status, alcohol intake, regular exercise, family history of diabetes and education level, BMI 191 
≥25kg/m2; all MetS factors; IR; and inflammation, the aHR (95% CIs) for the association 192 
between fatty liver and incident T2DM was 2.03 (1.73, 2.38) for men, and 3.09 (2.04, 4.67) for 193 
women. 194 
Next, we investigated the numbers of incident cases of diabetes, incidence of diabetes per 195 
10,000 patient years, and age-adjusted and fully adjusted HRs for incident diabetes in obese 196 
men and women combined (Table 4). Compared to the reference group (n = 19,757), (crude 197 
incidence rate for diabetes = 143.0 cases/10,000 person-years), in the obese group without MetS 198 
components, crude incidence rate for diabetes = 28.8 cases/10,000 person-years) and aHR (95% 199 
CIs) for incident diabetes was 0.25 (0.20, 0.31). In the obese group without MetS components, 200 
fatty liver or inflammation, crude incidence rate for diabetes = 12.6 cases/10,000 person-years) 201 
and aHR (95% CIs) for incident diabetes was 0.13 (0.06, 0.33). 202 
 203 
4. Discussion 204 
 205 
Our novel results show that in an obese Korean cohort, the incidence of type 2 diabetes is 206 
approximately 1.1% per annum and that there are marked differences in T2DM incidence within 207 
the cohort, depending on the presence or absence of metabolic abnormalities. Incidence of 208 
T2DM was ~90% lower among obese people who do not have any other MetS components, or 209 
evidence of IR, inflammation and fatty liver, than among the group with one or more of these 210 
metabolic abnormalities. The overall incidence of T2DM in our study is similar to that described 211 
in many cohorts from different regions around the world [1,25-29]. 212 
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Current population-based prevalence of NAFLD is approximately 30-40% in men and 15-213 
20% in women [6] and is even higher in people with T2DM, occurring in up to 70% of this 214 
group of patients [7]. Recent evidence shows that liver fat, as a manifestation of NAFLD, is a 215 
risk factor for both T2DM and CVD [5,30,31]. Given that liver fat is very common in patients 216 
with obesity [32], and can be diagnosed with ultrasound, identification of fatty liver provides a 217 
potentially useful strategy for finding subjects at increased risk of diabetes in obese subjects. 218 
Obesity is a risk factor for increased all cause mortality [33-35] and a recent meta-analysis 219 
investigating whether MHO is ever a benign condition, suggested that obese persons are at 220 
increased risk of cardiovascular events, even in the absence of metabolic abnormalities [36]. 221 
These findings led the authors of the meta-analysis to conclude that there is no healthy pattern 222 
of increased weight. However many of the studies included in the meta-analysis adjusted for 223 
different metabolic risk factors [37-39], and the summary results of the meta-analysis were 224 
presented as crude hazard ratios. These data emphasise that further research is needed to test 225 
whether obesity is ever a metabolically benign condition, having adjusted for a comprehensive 226 
range of risk factors for metabolic and vascular disease. The optimum BMI associated with 227 
metabolic health is not clear and may vary by ethnic group and sex. A recent large meta-analysis 228 
showed that the associations of both overweight and obesity with higher all-cause mortality 229 
were broadly consistent across 10,625,411 participants from different ethnic groups in Asia, 230 
Australia and New Zealand, Europe, and North America (data from 239 prospective studies) 231 
across four continents [35]. However, that said, a recent study of 12.8 million Korean adults, 232 
aged 18-99 years, suggested that the BMI which predicted the lowest mortality increased with 233 
age and was lower in women than men [40]. The change in optimum BMI with age was also 234 
more profound in women than in men and sex and age-specific optimums for BMI were 235 
generally higher than for the current normal range (BMI of 18.5-24.9kg/m2) (except for women 236 
< 50 years). Taken together, these data highlight the notion that BMI is an imprecise measure 237 
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of risk of ill health, and associations between BMI and ill health are likely to differ according 238 
to age, sex and the presence of other risk factors such as those studied herein. In keeping with 239 
the data we have presented, we suggest that in order to improve the clinical utility of BMI to 240 
assess risk of incident disease in obese subjects, it is important to consider the co-existing 241 
presence of fatty liver, IR and inflammation besides more traditional risk factors. Assessment 242 
of these easily measured risk factors may improve the prognostic value of BMI as an indicator 243 
of future risk of T2DM and importantly, allow limited resources available for diabetes 244 
prevention to be targetted at higher risk obese sub-groups. 245 
Recently, the issue of whether MHO exists as a phenomenon, has been discussed in an 246 
editorial [33] based on the work of Yi et al [40], with the authors of the editorial concluding 247 
that MHO is common among the obese population and constitutes a unique subset of protective 248 
characteristics that reduce metabolic and cardiovascular risk factors despite the presence of 249 
excessive fat mass. However, it was acknowledged that the protective factors that grant a 250 
healthier profile to individuals with MHO are poorly understood and are still being elucidated. 251 
Numerous possible mechanisms underlying the explanation for MHO have been suggested, 252 
including adipose tissue distribution and an absence of inflammation. However, the prognostic 253 
value of MHO remains controversial [41-43] and the lack of a standard definition for metabolic 254 
health and obesity (as well as the dynamic properties of MHO) may have contributed to 255 
contrasting results regarding the prognostic value of MHO [44]. Whilst our manuscript was 256 
under review a meta-analysis of three studies with 132,667 subjects including 8675 MHO 257 
subjects without fatty liver, and 7218 MHO subjects with fatty liver, suggested that that the 258 
MHO phenotype, with or without fatty liver, presents a risk of the development of type 2 259 
diabetes [45].  However, our data emphasise that if a term such as MHO is to be used, it should 260 
be defined by including subjects with obesity, only after exclusion of inflammation, IR and 261 
fatty liver, as well as exclusion of easily measured components of the MetS (dysglycaemia, 262 
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atherogenic dyslipidaemia – low levels of HDL-C and high levels of serum triglyceride 263 
concentrations, and increased blood pressure). Whilst exclusion of inflammation, IR, fatty liver 264 
and easily measured components of the MetS did not completely abolish the risk of diabetes 265 
associated with obesity; exclusion of these factors did markedly attenuate the risk of diabetes 266 
over ~4 years of follow up. 267 
The strengths and limitations of our study should be considered. We have studied a large 268 
number of obese individuals (n = 29,836) with ~4 years of follow up. There were a substantial 269 
number (n = 1,200), incident cases of diabetes at follow up. As an oral glucose tolerance test 270 
was not undertaken to identify prevalent or incident diabetes, it is possible that some 271 
misclassification bias occurred. However, any such bias would not be expected to be differential, 272 
so would attenuate the strength of the observed associations, and would bias associations 273 
towards the null. We have also assessed the presence of fatty liver using abdominal 274 
ultrasonography at baseline. Whilst the sensitivity of ultrasound for detecting fatty liver is 275 
limited to identification of ~>25% fat infiltration [24], and the detection of liver fat can be 276 
affected by severe obesity, in our predominantly single ethnic group population, there were very 277 
few severely obese subjects. Although we acknowledge that it is possible that subjects with low 278 
levels of liver fat compatible with a diagnosis of NAFLD would not have been identified by 279 
ultrasound, any misclassification bias would attenuate the strength of the associations we have 280 
observed. Additionally, another important limitation is that it was not possible to assess the 281 
effect of waist circumference (a key component of the MetS) in these subjects. However, despite 282 
widespread evidence that waist circumference is a better indicator of future risk, waist 283 
circumference is rarely measured in clinical practice and BMI remains the more frequently used 284 
simple measure for assessing obesity. Given that BMI is the much more frequently used 285 
measure, it is therefore clinically relevant to ascertain what factors added to obesity contribute 286 
markedly to increasing risk of T2DM, in order to determine what factors have to be excluded 287 
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to define MHO. In this cohort, waist circumference was only available on a proportion of 288 
subjects, and therefore we considered it more appropriate to use the BMI threshold ≥25kg/m2 289 
as well as the other recognized features of the MetS to define the presence or absence of the 290 
syndrome. Finally, HbA1c was not measured using a method standardized to the Diabetes 291 
Control and Complications Trial and approved by the National Glycohemoglobin 292 
Standardization Program. 293 
 294 
5. Conclusion 295 
 296 
Our results add to existing evidence by showing that obese subjects who do not have 297 
increased blood pressure, dyslipidaemia, impaired fasting glucose, IR, fatty liver and 298 
inflammation are at very low risk of incident diabetes at ~4 year follow up. We suggest that 299 
measuring these simple easily measured risk factors in obese individuals would be useful to 300 
assess risk of T2DM in clinical practice. Although further work is necessary to test the 301 
durability of our findings over a longer period of follow up, we suggest that measurement, and 302 
exclusion of these risk factors in clinical practice, may help better targeting of limited resources 303 
for diabetes prevention to obese people at highest risk of developing diabetes. 304 
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Tables 446 
Table 1 
Baseline characteristics of the whole cohort according to incident DM 
Characteristics No DM Incident DM p value 
Number (%) 28,636 (96.0) 1,200 (4.0)  
Age (years)* 36±6 39±6 <0.001 
Male, n (%) 23,052 (80.5) 973 (81.1) 0.617 
Systolic BP (mmHg)* 115±10 117±10 <0.001 
Diastolic BP (mmHg)* 74±7 75±7 <0.001 
Glucose (mg/dl)* 95±8 106±10 <0.001 
Total cholesterol (mg/dl)* 200±32 206±33 <0.001 
LDL-C (mg/dl)* 124±29 128±29 <0.001 
HDL-C (mg/dl)* 49±11 46±10 <0.001 
Triglycerides (mg/dl)† 128 (92-181) 158 (115-221) <0.001 
ALT (IU/L)† 27 (19-40) 36 (24-55) <0.001 
AST (IU/L)† 23 (19-29) 27 (22-35) <0.001 
GGT (IU/L)† 30 (19-49) 42 (27-69) <0.001 
hsCRP†(mg/l)† 0.07 (0.04-0.13) 0.09 (0.05-0.2) <0.001 
HOMA-IR† 1.56 (1.09-2.17) 2.25 (1.58-3.16) <0.001 
Smoking, n (%)   <0.001 
Current smoker 10,357 (36.2) 505 (42.1)  
Never/former smoker 17,258 (60.3) 663 (55.3)  
Unknown 1,021 (3.6) 32 (2.7)  
Alcohol intake, n (%)   0.065 
<20g/day 21,180 (74.0) 868 (72.3)  
21 
20g/day 5,558 (19.4) 263 (21.9)  
Unknown 1,898 (6.6) 69 (5.8)  
Regular exercise, n (%)§   0.319 
<1 times per week 14,834 (51.8) 595 (49.6)  
≥1 times per week 13,359 (46.7) 585 (48.8)  
Unknown 443 (1.6) 20 (1.7)  
Family history of DM, n (%)   <0.001 
No 23,837 (83.24) 892 (74.33)  
Yes 4,666 (16.30) 296 (24.67)  
Unknown 133 (0.46) 12 (1.00)  
High education level, n (%)   <0.001 
≤High school 1,589 (5.6) 54 (4.5)  
≥College graduate 12,081 (42.2) 406 (33.8)  
Unknown 14,966 (52.3) 740 (61.7)  
Seoul center, n (%) 14,758 (51.5) 615 (51.3) 0.846 
BMI (kg/m2) 27±2 28±2 <0.001 
Fatty liver, n (%)   <0.001 
No 12,697 (44.4) 276 (23.0)  
Yes 15,910 (55.6) 923 (77.0)  
MetS, n (%) 8,377 (29.3) 744 (62.0) <0.001 
Inflammation (hsCRP >1mg/L), n (%) 9,454 (33.0) 540 (45.0) <0.001 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, 
blood pressure; DM, diabetes; GGT, gamma-glutamyl transferase; HDL-C, high-density 
lipoprotein-cholesterol; HOMA-IR, homeostatic model assessment-Insulin resistance; hs 
CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol. 
22 
Data are *mean (standard deviation), †median (interquartile range). 
§
 ≥1 time per week. 
447 
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Table 2 
Baseline characteristics according to obesity type (men) 
  All obese(A) Obese, without MetS 
components (B) 
Obese, without MetS components, 
fatty liver or inflammation (C) 
p value 
Number (%) 24,025 16,441 (68.43) 6,376 (26.54) 1,208 (5.03)  
Age (years)* 36±6 37±6 36±6 35±6 <0.001 
Systolic BP (mmHg)* 117±9 118±10 114±8 112±8 <0.001 
Diastolic BP (mmHg)* 75±7 76±7 73±6 70±7 <0.001 
Glucose (mg/dl)* 96±8 98±8 91±6 91±5 <0.001 
Total cholesterol (mg/dl)* 202±32 205±33 197±30 193±29 <0.001 
LDL-C (mg/dl)* 126±29 127±30 124±28 123±28 <0.001 
HDL-C (mg/dl)* 48±10 46±10 52±9 56±11 <0.001 
Triglycerides (mg/dl)† 138 (100-192) 168 (124-219) 103 (81-124) 90 (70-112) <0.001 
ALT (IU/L)† 30 (22-43) 32 (23-46) 27 (20-39) 22 (17-30) <0.001 
AST (IU/L)† 24 (20-30) 25 (21-31) 24 (20-28) 21 (18-25) <0.001 
GGT (IU/L)† 35 (24-55) 39 (26-61) 29 (21-44) 25 (18-36) <0.001 
hsCRP(mg/l)† 0.07 (0.04-0.13) 0.07 (0.04-0.13) 0.07 (0.04-0.14) 0.03 (0.02-0.05) <0.001 
24 
HOMA-IR† 1.65 (1.13-2.35) 1.95 (1.37-2.76) 1.40 (0.99-1.97) 1.19 (0.81-1.61) <0.001 
Smoking, n (%)     <0.001 
Current smoker 10,582 (44.05) 7,621 (46.35) 2,515 (39.44) 446 (36.92)  
Never/former smoker 12,829 (53.40) 8,401 (51.1) 3,725 (58.42) 703 (58.2)  
Unknown 614 (2.56) 419 (2.55) 136 (2.13) 59 (4.88)  
Alcohol intake, n (%)     <0.001 
<20g/day 19,931 (82.96) 11,714 (71.25) 4,885 (76.62) 800 (66.23)  
20g/day 3,110 (12.94) 4,070 (24.76) 1,233 (19.34) 339 (28.06)  
Unknown 984 (4.10) 657 (4) 258 (4.05) 69 (5.71)  
Regular exercise, n (%)§     0.136 
<1 times per week 11,872 (49.42) 8,321 (50.61) 3,024 (47.43) 527 (43.63)  
≥1 times per week 11,835 (49.26) 7,902 (48.06) 3,272 (51.32) 661 (54.72)  
Unknown 318 (1.32) 218 (1.33) 80 (1.25) 20 (1.66)  
Family history of DM, n (%)     0.007 
No 20,129 (83.78) 13,631 (82.91) 5,474 (85.85) 1,024 (84.77)  
Yes 3,792 (15.78) 2,732 (16.62) 877 (13.75) 183 (15.15)  
Unknown 104 (0.43) 78 (0.47) 25 (0.39) 1 (0.08)  
25 
High education level, n (%)     <0.001 
≤High school 851 (3.54) 608 (3.7) 178 (2.79) 65 (5.38)  
≥College graduate 10,752 (44.75) 7,070 (43) 2,813 (44.12) 869 (71.94)  
Unknown 12,422 (51.70) 8,763 (53.3) 3,385 (53.09) 274 (22.68)  
Seoul center, n (%) 11,413 (47.5) 8,196 (49.85) 2,751 (43.15) 466 (38.58) <0.001 
BMI (kg/m2) 27 ± 2 27 ± 2 27 ± 2 26 ± 1 <0.001 
Fatty liver, n (%)     <0.001 
No 9,318 (38.78) 5,356 (32.6) 2,754 (43.24) 1,208 (100)  
Yes 14,688 (61.14) 11,073 (67.4) 3,615 (56.76) -  
Unknown 19 (0.08) 12 (0.07) 7 (0.11) -  
MetS, n (%) 7,828 (32.58) 7,828 (47.61) - - <0.001 
Inflammation (hsCRP >1mg/L), n (%) 7,750 (32.26) 5,571 (33.88) 2,179 (34.18) - <0.001 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; DM, diabetes; GGT, gamma-glutamyl 
transferase; HDL-C, high-density lipoprotein-cholesterol; HOMA-IR, homeostatic model assessment-Insulin resistance; hs CRP, high-sensitivity C-
reactive protein; LDL-C, low-density lipoprotein cholesterol. 
Data are *mean (standard deviation), †median (interquartile range). 
§
 ≥1 time per week. 
26 
Table 3 
Baseline characteristics according to obesity type (women) 
 
 All obese(A) Obese, without MetS 
components (B) 
Obese, without MetS components, 
fatty liver or inflammation (C) 
p value 
Number (%) 5,811 3,316 (57.06) 1,986 (34.18) 509 (8.76)  
Age (years)* 38±7 38±7 37±7 37±6 <0.001 
Systolic BP (mmHg)* 110±11 112±11 108±9 105±9 <0.001 
Diastolic BP (mmHg)* 69±8 71±8 68±7 66±7 <0.001 
Glucose (mg/dl)* 94±8 96±9 90±6 90±6 <0.001 
Total cholesterol (mg/dl)* 195±33 195±36 196±30 189±28 <0.001 
LDL-C (mg/dl)* 118±29 120±30 115±28 113±25 <0.001 
HDL-C (mg/dl)* 55±12 50±11 62±10 64±10 <0.001 
Triglycerides (mg/dl)† 98 (73-137) 120 (87-169) 82 (64-104) 73 (56-92) <0.001 
ALT (IU/L)† 17 (13-23) 18 (14-25) 16 (13-22) 14 (11-18) <0.001 
AST (IU/L)† 19 (16-23) 19 (17-24) 19 (17-23) 17 (15-20) <0.001 
GGT (IU/L)† 15 (11-22) 17 (12-25) 14 (11-20) 13 (11-17) <0.001 
hsCRP (mg/l)† 0.08 (0.04-0.16) 0.09 (0.05-0.18) 0.08 (0.04-0.17) 0.03 (0.02-0.05) <0.001 
27 
HOMA-IR† 1.65 (1.13-2.35) 1.95 (1.37-2.76) 1.40 (0.99-1.97) 1.19 (0.81-1.61) <0.001 
Smoking, n (%)     <0.001 
Current smoker 280 (4.82) 173 (5.22) 93 (4.68) 14 (2.75)  
Never/former smoker 5,092 (87.63) 2,891 (87.18) 1,769 (89.07) 432 (84.87)  
Unknown 439 (7.55) 252 (7.6) 124 (6.24) 63 (12.38)  
Alcohol intake, n (%)     <0.001 
<20g/day 4,649 (80.0) 2,679 (80.79) 1,620 (81.57) 350 (68.76)  
20g/day 179 (3.08) 92 (2.77) 57 (2.87) 30 (5.89)  
Unknown 983 (16.92) 545 (16.44) 309 (15.56) 129 (25.34)  
Regular exercise, n (%)§     <0.001 
<1 times per week 3,557 (61.21) 2,021 (60.95) 1,201 (60.47) 335 (65.82)  
≥1 times per week 2,109 (36.29) 1,206 (36.37) 742 (37.36) 161 (31.63)  
Unknown 145 (2.50) 89 (2.68) 43 (2.17) 13 (2.55)  
Family history of DM, n (%)     <0.001 
No 4,600 (79.16) 2,574 (77.62) 1,620 (81.57) 406 (79.76)  
Yes 1,170 (20.13) 717 (21.62) 351 (17.67) 102 (20.04)  
Unknown 41 (0.71) 25 (0.75) 15 (0.76) 1 (0.2)  
28 
High education level, n (%)     <0.001 
≤High school 792 (13.63) 480 (14.48) 204 (10.27) 108 (21.22)  
≥College graduate 1,735 (29.86) 885 (26.69) 559 (28.15) 291 (57.17)  
Unknown 3,284 (56.51) 1,951 (58.84) 1,223 (61.58) 110 (21.61)  
Seoul center, n (%) 3,050 (52.49) 1,810 (54.58) 1,009 (50.81) 231 (45.38) <0.001 
BMI (kg/m2) 27±2 27±2 27±2 26±1 <0.001 
Fatty liver, n (%)     <0.001 
No 3,655 (62.90) 1,778 (53.62) 1368 (68.88) 509 (100)  
Yes 2,145 (36.91) 1,534 (46.26) 611 (30.77) -  
Unknown 11 (0.19) 4 (0.12) 7 (0.35) -  
MetS, n (%) 1,293 (22.25) 1,293 (38.99) - - <0.001 
Inflammation (hsCRP >1mg/L), n (%) 2,244 (38.62) 1,430 (43.12) 814 (40.99) - <0.001 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; DM, diabetes; GGT, gamma-glutamyl 
transferase; HDL-C, high-density lipoprotein-cholesterol; HOMA-IR, homeostatic model assessment-Insulin resistance; hs CRP, high-sensitivity C-
reactive protein; LDL-C, low-density lipoprotein cholesterol. 
Data are *mean (standard deviation), †median (interquartile range). 
§
 ≥1 time per week. 
29 
 448 
Table 4 
Numbers of incident DM, incident DM rates and hazard ratios (HRs) for all incident DM in obese subjects 
Obese groups Number Median (IQR) 
f/up(Days) 
Person-years Number 
of events 
Incident DM 
(10,000person-year) 
Model 1Age-adjusted 
HRs (95% CI)* 
Model 2Multivariate HRs 
(95% CI)* 
All 29,836       
A 19,757 1,408 (735-2,154) 76,870.8 1,099 143.0 1 (reference) 1 (reference) 
B 8,362 1,418 (741-2,143) 33,276.9 96 28.8 0.25 (0.20-0.31) 0.25 (0.20-0.31) 
C 1,717 743 (641-1,082) 3,971.2 5 12.6 0.16 (0.07-0.38) 0.13 (0.06-0.33) 
p for trend      <0.001 <0.001 
Men 24,025       
A 16,441 1,414 (735-2,157) 64,325.9 896 139.3 1 (reference) 1 (reference) 
B 6,376 1,415 (739-2,141) 25,366.9 73 28.8 0.26 (0.20-0.33) 0.25 (0.20-0.33) 
C 1,208 735 (634-1,034) 2,735.3 4 14.6 0.20 (0.07-0.52) 0.16 (0.06-0.44) 
p for trend      <0.001 <0.001 
Women 5,811       
A 3,316 1,383 (735-2,128) 1,2544.9 203 161.8 1 (reference) 1 (reference) 
30 
B 1,986 1,429 (743-2,151) 7,910.0 23 29.1 0.22 (0.14-0.34) 0.22 (0.14-0.35) 
C 509 770 (655-1,203) 1,235.9 1 8.1 0.09 (0.01-0.61) 0.07 (0.01-0.51) 
p for trend      <0.001 <0.001 
Group A (reference group) (n = 19,757 (66.22%) = obese subjects with ≥1 component of MetS (i.e. dysglycaemia, low levels of HDL-C, high levels 
of serum triglyceride concentrations, or increased blood pressure [22]); or fatty liver (defined by presence of fatty liver on ultrasound), or IR (defined 
by HOMA-IR≥2.5), or inflammation (defined by hsCRP≥1mg/L). 
Group B (n = 8,362 (28.03%) = obese subjects without features of the MetS [22], but with ≥1 of fatty liver, IR, or inflammation (defined as above). 
Group C (n = 1,717 (5.75%) = obese subjects without features of the MetS [22], fatty liver, IR or inflammation (defined as above). 
*Adjustments: Model 1 = Age, Model 2 Age, sex, center, year of screening exam, smoking status, alcohol intake, regular exercise, Family history of 
DM and education level. 
Median interquartile range (IQR) follow up (F/U) (days). 
 449 
  450 
31 
 451 
0 
-2 
-4 
-6 
-8 
L
o
g
(
-
l
o
g
 
S
(
t
)
)
 
Supplementary figure 1. Graphical analysis to test proportional hazards assumption for t
hree obesity groups  
 and risk of incident diabetes over time    
